


Report of the OECD Accreditation and Designation Programme

26 May 2021 – General Assembly

Simon Oberst,

Chair of the A&D Board



What is the OEI Accreditation and Designation Programme aiming to achieve?

- To drive quality improvements for patients
- To provide an independent and objective external quality assessment of Centres
- To provide quality standards which are ambitious in terms of excellence
- To provide pan-European standards which can be applied in **any** European country **and beyond**



What are the advantages of an OECI accreditation?

- It is the only Europe-wide institutional accreditation which covers both cancer care and research
- The Review produces a high quality Improvement Plan (with clear identification of opportunities and a plan to fix them)
- There is a real engagement by all disciplines and all levels of staff
- The gathering of the data and the self assessment by all departments is a benefit in itself (for self monitoring and learning)
- The programme reached 52 European centres in 2021, many more in the pipeline



How does the A&D Programme add value for patients?

- There are large sections of the questionnaires around patient satisfaction and involvement in the centre
- The peer review is part of a toolbox to improve outcomes for patients
- It disseminates research and implementation of best practice
- The process spurs collaboration and the development of networks



The A&D Board 2020/21


- Simon Oberst, Cambridge, Chair
- Wim van Harten, Arnhem, The Netherlands
- Paolo de Paoli, ACC network, Italy
- Peter Nagy, Budapest
- Jean-Benoît Burrion, Brussels
- Gunnar Sæter, Oslo
- Eva Gustafsson, Stockholm
- Mef Nilbert, Copenhagen
- Jozsef Lovey, Budapest (chair of Accreditation Committee)

The Accreditation Committee 2020/21

- Jozsef Lovey, Budapest (Chair)(Previously Gunnar Saeter – whom, thanks!)
- Henk Hummel, Groningen
- Irène Philip, Lyon
- Marek Svoboda, Brno
- Mari-Leen Pärn, Estonia
- Jorrit Enserink, Oslo
- Francesco Monetti (until January 2021 – many thanks)
- Rui Silva, Coimbra (until January 2021 – many thanks)

Many thanks to the support from:

- The IKNL team: Harriët Blaauwgeers; Willien Westerhuis; Annemiek Kwast (till Nov 2020); Jolanda van Hoeve; Heidi van Doorne; Sylvia Blommestein.
- At Cambridge: Kelly O'Reilly
- At Genova (SOS Europe): Claudio Lombardo; Giorgia Pesce; Daniela Garbarino; Patrizia Sommella and Roxanna Plesoianu




52 centres now in the programme



Accredited - Cancer Centre - 16

Accredited - Comprehensive Cancer Centre - 24

Newly in the accreditation process - 12




Centres with a Peer Review in 2021

- Istituto Tumori, Milan, Italy 2nd
- CROB Basilicata, Italy 2nd
- Kuopio University Hospital, Finland
- Skåne University Hospital, Lund, Sweden
- Sahlgrenska University Hospital, Gothenburg, Sweden
- Vejle Cancer Centre, Denmark 2nd
- Beaumont Cancer Centre, Dublin
- Tartu Cancer Centre, Estonia 2nd
- Candiolo Cancer Institute, Turin, Italy
- Groningen University Hospital, The Netherlands
- Ljubljana Cancer Centre, Slovenia
- AP-HP CARPEM Paris, France

Network

- ATOP network - Toulouse



The programme is growing across Europe and beyond

- Growth in applications across France to the majority of Cancer Centres
- Substantial growth in the Nordic Countries – complete in Finland
- New centres in Spain
- Nearly complete coverage in Italy and Portugal

- Interest from Poland, Denmark, Chile, Colombia, Vietnam, China, Dublin, Latvia

- Our total cohort of centres produce more than 12,400 research papers annually, have annual research budgets of more than €1 billion, and have treated more than 1 million new cancer patients since their accreditations



Important developments

- Great success with virtual and semi-virtual peer reviews (9)
- More than 65 trained auditors in many different disciplines.
- New standards for Cancer Networks/Infrastructures (piloted in France in March 2021) – shortly to be published
- Participating in iPAAC WP7 and WP10
- Significant input into European Commission and Cancer Mission Board re the planning of Cancer Mission and Beating Cancer Plan.
- Excellent Practices project to disseminate – 26 practices across Europe – for Summer 2021
- Steps to improve our Communications
- A&D Standards going through ISQua re-accreditation
- Manual 3.0 is now operational



Papers published and in preparation

Published

1. 100 European core quality standards for cancer care and research centres. *Oberst et al, Lancet Oncology, August 2020*
2. Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks. *Kehrloesser et al, Molecular Oncology, March 2021*

In preparation

1. Evaluating Comprehensive Cancer Networks; a new tool to drive up quality – featuring OECD's new European Standards
2. What is a roadmap to creating successful CCCs out of University Medical Centres? – especially relevant to the EU Cancer Mission objective to create Comprehensive Cancer Infrastructures in every Member State.

EU Cancer Mission and Europe's Beating Cancer Plan


- Recommendation 10 of the Cancer Mission Board:

Set up a Network of Comprehensive Cancer Infrastructures within and across all EU member states to improve the quality of research and care.

- EBCP Flagship 5 to set up a EU Network of National CCCs by 2025 – to reach 90% of eligible patients by 2030 – reinforces that purpose.

Joint aims

- Diminish inequalities of access to treatment and access to clinical trials
- Harmonise standards of care and research using accreditation standards



● OECI Comprehensive Cancer Centre (CCC)

www.oeci.eu/accreditation

● OECI Cancer Centre

www.oeci.eu/accreditation

● In OECI Accreditation & Designation Process


www.oeci.eu/accreditation

● EACS Designation of Research Excellence and OECI CCC

www.europecancercanceracademy.eu

● Oncologische Spitzenzentren of Deutsche Krebshilfe

www.ccc-netzwerk.de/das-netzwerk/mitglieder.html



EU countries with almost full coverage of accredited centres:

- Italy
- France
- Germany
- Finland
- Portugal

EU countries with no accredited centres yet:

- Slovakia
- Greece
- Croatia
- Bulgaria
- Malta
- Cyprus
- Latvia (applying)
- Poland (applying)
- Slovenia (in progress)
- Luxembourg (in progress)

The emphasis should be on formation and improvement of centres/networks, prior to accreditation

- OECI has expertise to consult **at a local infrastructure level** to get there....
 - Advice on governance and organisation (centres and networks)
 - Advice on multidisciplinary (MDTs+researchers)
 - Consultancy around clinical trials organisation and recruitment
 - Consultancy on data, samples, standardisation
 - Tracking outcomes and treatment optimisation
 - Knowledge exchange programmes
 - Sharing excellent practices
- Accreditation is then helpful as part of an improvement process to address Innovation, Implementation, Inequalities.



Thank you for your attention

